← back to search

Zhen‐Huan Hu

Gilead Sciences (Australia) · AU
🔎 Find collaborators in Hematology · Oncology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Hematology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, and Lymphoma Diagnosis and Treatment.
h-index
26
citations
3,357
works
115
NIH funding
primary concept
Medicine
email

Recent publications

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Blood Advances 2025cited by 10position: middledoi
Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Blood 2024cited by 10position: middledoi
Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics
Blood 2023cited by 10position: middledoi
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages
Blood 2022cited by 89position: middledoi
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors
JAMA Oncology 2022cited by 76position: middledoi
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Blood Advances 2020cited by 431position: middledoi
Survival following allogeneic transplant in patients with myelofibrosis
Blood Advances 2020cited by 96position: middledoi
Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i>− MPN with de novo AML and with AML following MDS
Blood Advances 2020cited by 19position: middledoi
Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
Blood 2019cited by 95position: middledoi
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood &amp; Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Blood 2019cited by 78position: middledoi
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
Biology of Blood and Marrow Transplantation 2019cited by 35position: middledoi
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
Blood Advances 2018cited by 42position: middledoi
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
New England Journal of Medicine 2017cited by 766position: middledoi
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia
Biology of Blood and Marrow Transplantation 2017cited by 62position: middledoi
Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes
Biology of Blood and Marrow Transplantation 2017cited by 22position: middledoi
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
Biology of Blood and Marrow Transplantation 2015cited by 36position: middledoi
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
Blood 2014cited by 216position: middledoi
Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma
Biology of Blood and Marrow Transplantation 2014cited by 42position: middledoi
Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
Biology of Blood and Marrow Transplantation 2013cited by 144position: middledoi
Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402
Blood 2012cited by 23position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Marcelo C. Pasquini · Medical College of Wisconsin6 papers (2012–2024)Mary M. Horowitz · Medical College of Wisconsin4 papers (2012–2019)Alex F. Herrera · City Of Hope National Medical Center3 papers (2019–2024)Caron A. Jacobson · Harvard University3 papers (2019–2024)Joseph H. Antin · Boston University3 papers (2012–2017)Ryotaro Nakamura · Beckman Research Institute3 papers (2012–2022)Soyoung Kim · Hanwha Techwin (South Korea)3 papers (2022–2024)Frederick L. Locke · Moffitt Cancer Center3 papers (2019–2024)Corey Cutler · Harvard University3 papers (2012–2017)Peiman Hematti · Medical College of Wisconsin2 papers (2019–2019)Patricia Steinert · Medical College of Wisconsin2 papers (2019–2019)Mazyar Shadman · Fred Hutch Cancer Center2 papers (2023–2024)Laura Johnston · Inova Health System2 papers (2012–2014)Wael Saber · Benha University2 papers (2017–2022)Sung Won Choi · Michigan Cancer Research Consortium2 papers (2012–2014)Philip L. McCarthy · Roswell Park Comprehensive Cancer Center2 papers (2012–2014)Stephen R. Spellman · Memorial Sloan Kettering Cancer Center2 papers (2017–2022)Stephan A. Grupp · University College London2 papers (2012–2014)R. Coleman Lindsley · Harvard University2 papers (2017–2022)William J. Hogan · University of California San Diego2 papers (2012–2014)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Hematology · Oncology →